Table 1 Multivariate Cox regression analysis for OS including age >65Â years, cytogenetic and molecular risk factors, gender, and TriAS in the TCGA training and all validation sets if available are shown
From: A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
| Â | HR multivariate | p value multivariate |
|---|---|---|
TCGA training set (n = 154) | ||
 Cytogenetic risk group poor | 1.505 (0.896–2.527) | 0.1222 |
 Cytogenetic risk group favorable | 0.448 (0.228–0.881) | 0.0200 |
 FLT3 mutated | 1.590 (0.946–2.672) | 0.0799 |
 NPM1 mutated | 0.718 (0.419–1.229) | 0.2267 |
 Gender (female) | 1.192 (0.790–1.797) | 0.4033 |
 Age > 65 | 4.472 (2.818–7.098) | <0.0001 |
 TriAS | 1.978 (1.505–2.600) | <0.0001 |
GPL570 training set (n = 79) | ||
 Age > 65 | 1.683 (0.943–3.007) | 0.0784 |
 TriAS | 2.147 (1.557–2.961) | <0.0001 |
NTUH validation set 1 (n = 221) | ||
 Cytogenetic risk group poor | 2.504 (1.547–4.052) | 0.0002 |
 Cytogenetic risk group favorable | 0.434 (0.234–0.802) | 0.0077 |
 CEBPA mutated | 0.248 (0.098–0.629) | 0.0033 |
 FLT3 mutated | 2.034 (1.320–3.135) | 0.0013 |
 NPM1 mutated | 0.801 (0.483–1.328) | 0.3893 |
 Gender (female) | 0.779 (0.526–1.152) | 0.2109 |
 Age > 65 | 2.064 (1.258–3.389) | 0.0042 |
 TriAS | 1.393 (1.097–1.769) | 0.0066 |
GPL96 validation set 2 (n = 163) | ||
 Age > 65 | 1.639 (1.097–2.449) | 0.0159 |
 TriAS | 1.239 (1.014–1.515) | 0.0361 |